64 Cu-based Radiopharmaceuticals in Molecular Imaging

Abstract

Copper-64 (T_1/2 = 12.7 hours; β⁺: 19%, β⁻: 38%) has a unique decay profile and can be used for positron emission tomography imaging and radionuclide therapy. The well-established coordination chemistry of copper allows for its reaction with different types of chelator systems. It can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules. Two potential ways to produce copper-64 radioisotopes concern the use of the cyclotron or the reactor. This review summarized several commonly used biomarkers of copper-64 radionuclide.

Keywords

copper-64 PET/CT

Introduction

As molecular imaging continues to advance, positron emission tomography (PET) and single photon emission computed tomography (SPECT) technology are nowadays an integral part of the molecular imaging toolbox. Dual-modality imaging, such as PET/computed tomography (CT) or SPECT/CT, integrates the high-resolution anatomical images with physiological information, which enables the investigators to identify the physiological basis of the disease and correlate it with the anatomical image.¹

Radioactive copper is one of the most actively studied radionuclides.^2
–4 Several reasons render this element so attractive for PET imaging. The long half-life of the copper allows sufficient uptake and distribution to yield considerable contrast and quality of images. In addition, copper can react with many chelator systems due to its well-established coordination chemistry, and it can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules.⁵ The most extensively used class of chelators for ⁶⁴Cu has been shown in Figure 1. Among the 27 known copper radioisotopes, 5 of them are particularly interesting for molecular imaging applications (⁶⁰Cu, ⁶¹Cu, ⁶²Cu, and ⁶⁴Cu) and in radiotherapy (⁶⁴Cu and ⁶⁷Cu).⁴ Table 1 lists their nuclear characteristics.

Figure 1.

DOTA, CU-ATSM, CB-TE2A, and TETA the most common bifunctional chelators used for labeling biomolecules. DOTA indicates 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; ATSM, Diacetyl bis(N 4-methylthiosemicarbazone); CB-TE2A, 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane; TE2A, 1,4,8,11-tetraazacyclotetradecane-1,8-diacetic acid.

Table 1.

Decay Characteristics of Copper Radioisotopes.

Isotope	T_1/2	Decay Mode	Energy, Kev
⁶⁰Cu	23.7 min	β⁺ (93%)	2940,3920
⁶⁰Cu	23.7 min	γ (7%)	511-467-826-1332
⁶¹Cu	3.3 h	β⁺ (60%)	1220,1159
⁶¹Cu	3.3 h	γ (40%)	511-283-589-656
⁶²Cu	9.7 min	β⁺ (98%)	2925
⁶²Cu	9.7 min	γ (2%)	511
⁶⁴Cu	12.7 h	β⁺ (19%)	657
		γ (43%)	511-1346
		β⁻ (38%)	141
⁶⁷Cu	62.0 h	β⁻ (100%)	390-482-575
⁶⁷Cu	62.0 h	γ (52%)	91-93-185

Availability of Cu isotopes for preclinical and clinical research has been greatly improved in the recent years, since many potential chelators have been developed over the last decade. A number of compounds coupled with Cu have been proposed not only for PET diagnostic imaging but also for targeted radiotherapy of tumor. Table 2 lists the most popular radiopharmaceuticals that were modified to be used with ⁶⁴Cu for cancer imaging and therapy. In the present study, we aimed to systematically review several commonly used biomarkers of ⁶⁴Cu radionuclide.

Table 2.

⁶⁴Cu-Based Radiopharmaceuticals in Molecular Application.

Compound		Aim	Disease
⁶⁴Cu-ATSM		Imaging	Head and neck cancer,¹⁵ lung cancer,¹⁶ cervical cancer, ^18,19 gliosarcoma²⁰
⁶⁴Cu-ATSM		Therapy	Colon cancer²⁵
⁶⁴CuCl₂		Imaging	Brain tumors,³⁰ prostate cancer³³
⁶⁴Cu-antibodies	Trastuzumab	Imaging	Breast cancer³⁵
	Trastuzumab	Therapy	Breast cancer³⁷
	Cetuximab	Imaging	Targeting EGFR-expressing tumors⁵
	TRC105-Fab	Imaging	Breast cancer⁴⁵
⁶⁴Cu-α_νβ₃-targeting antibodies		Imaging	Glioblastomas; breast cancer; prostate cancer; malignant melanomas; ovarian carcinomas⁵
⁶⁴Cu-somatostatin analogues		Imaging	Neuroendocrine tumors⁵⁷
⁶⁴Cu-AE105		Imaging	Breast cancer,⁶⁵ lung cancer,⁶⁶ colorectal cancer,⁶⁷ prostate cancer,⁶⁸ bladder cancer⁶⁹
⁶⁴Cu- PSMA - 617		Imaging	Prostate cancer⁷⁷
⁶⁴Cu- DOTA-alendronate		Imaging	Breast cancer⁸²

Production of Cu Radioisotope

The 2 potential ways to produce Cu radioisotopes include the use of the cyclotron or the reactor.⁶ Copper-64, the most commonly used copper radionuclide, is characterized by a unique decay scheme (β⁺: 19%, β⁻: 38% and electron capture: 43%). Such property allows either cyclotron or reactor production, and the latter route results in either low-specific activity (n, γ) or high-specific activity (n, p) products.⁵

Szelecsenyi et al ⁷ proposed ⁶⁴Cu reaction on a biomedical cyclotron, and small irradiations were performed to demonstrate the feasibility of ⁶⁴Cu production by this method. At present, the most common production method for ⁶⁴Cu utilizes the ⁶⁴Ni (p, n) ⁶⁴Cu reaction,⁵ which yields a large quantity of nuclides with high-specific activity. However, such method needs enriched ⁶⁴Ni leading to increased overall costs.⁸

The target for producing ⁶⁴Cu is enriched ⁶⁴ Ni (99.6%).⁹ The ⁶⁴Ni is plated on the gold disk using a procedure modified from Piel et al.¹⁰ At Washington University School of Medicine, ⁶⁴Cu is produced on a CS-15 cyclotron using 15.5 MeV protons (15-45 μA beam current) by the ⁶⁴Ni(p, n) ⁶⁴Cu reaction. After bombardment, the ⁶⁴Cu is separated from the target nickel in a 1-step procedure using an ion-exchange column.⁹

⁶⁴Zn (n, p) ⁶⁴Cu reaction in nuclear reactor is another method for production of ⁶⁴Cu.¹¹ Most reactor-produced radionuclides are produced through thermal neutron reactions or (n, γ) reactions. Thermal neutrons have an advantage of relatively low cost, and its target material is of the same element as the product radionuclide. Meanwhile, in order to generate ⁶⁴Cu with a high specific activity, fast neutrons are employed to bombard the target in an (n, p) reaction. Unlike a thermal neutron reaction, a fast or highly energetic neutron has sufficient energy to eject a particle from the target nucleus.¹² However, many highly radioactive by-products of the reaction need to be removed and handled properly.¹

⁶⁴Cu-diacetyl-bis (N4-methylthiosemicarbazone)

Hypoxia is a pathological condition arising in living tissues when oxygen supply does not adequately cover the cellular metabolic demand. Tomlinson and Gray, for the first time, have demonstrated the presence of hypoxia in human tumors in the early 1960s,¹³ and the hypoxic tissue in the tumors has certain resistance to traditional radiotherapy and chemotherapy, leading to increased aggressiveness, metastatic spread, enhanced rate of recurrence, and ultimately poor outcomes.¹⁴ Therefore, an important relationship exists between the assessment of tumor hypoxia and prognosis. Hypoxic regions can be visualized by combination of PET and oxygen-dependent cellular uptake of radiopharmaceuticals. In recent years, Cu-diacetyl-bis (N4-methylthiosemicarbazone) (Cu-ATSM) labeled with a positron-emitting isotope of copper, such as ⁶⁰Cu, ⁶²Cu and ⁶⁴Cu, has been developed as an imaging agent targeting the hypoxic regions in tumors for use with PET.^15

–20 Cu-ATSM has high membrane permeability and low redox potential, and it can passively diffuse within the intracellular environment to maintain the stability of normal tissue.

Mechanisms underlying the selective uptake of ⁶⁴Cu-ATSM in hypoxic areas still remain largely unexplored. Fujibayashi et al ²¹ suggested that Cu(II)-ATSM reduction occurs only in hypoxic cells due to the abnormally reduced state of their mitochondria and does not occur in normoxic cells. With extensive research on ⁶⁴Cu-ATSM, another mechanism is that Cu(II)-ATSM is reduced by thiols and converted into Cu(I)-ATSM complex both in normal and in hypoxic cells.²² In normal cells, ⁶⁴Cu(I)-ATSM is again oxidized to ⁶⁴Cu(II)-ATSM and then freely diffused out of the cells.²³ Under hypoxic conditions, this complex is less stable than its bivalent form and progressively dissociated into H₂-ATSM and free Cu(I), which are then rapidly entrapped in intracellular proteins.²¹

McCall et al ¹⁵ assessed the role of ⁶⁴Cu-ATSM in head and neck squamous cell carcinoma (HNSCC) xenograft model through a combination of in vivo PET imaging and in vitro autoradiography and founded that the uptake of ⁶⁴Cu-ATSM in tumors was significantly higher than that in muscles. The PET image showed large tumor-to-muscle ratios, which were continually increased over an 18-hour period of imaging after injection. The results indicated that ⁶⁴Cu-ATSM uptake was specific for malignant expression. A prospective study¹⁶ assessed the prognostic significance of ⁶⁴Cu-ATSM in 18 patients with locally advanced non-small cell lung cancer (NSCLC; n = 7) or head and neck cancer (HNC; n = 11) before treatment. Semi-quantitative and quantitative parameters on PET were calculated, including standardized uptake value (SUV)_max, SUV_{ratio-to muscle}, SUV_mean, hypoxic tumor volume (HTV), and hypoxic burden (HB = HTV × SUV_mean). These data were subsequently correlated to disease outcomes, which were expressed in terms of progression-free survival calculated on a follow-up period with a median of 14.6 months. These analyses demonstrated that volumetric parameters were the most robust predictors of outcome, and patients with lower HTV and HB tend to have a better prognosis. Another prospective study¹⁷ also assessed the prognostic role of ⁶⁴Cu-ATSM PET/CT pretreatment in 11 patients with HNC (III-IV). No significant difference was found in SUV_max between early (1 hour post injection) and late (16 hours post injection) acquisitions. Moreover, ⁶⁴Cu-ATSM showed high sensitivity (true positive rate, the percentage of positives that are correctly identified; 100%) but low specificity (true negative rate, the percentage of negatives that are correctly identified) in predicting therapy response based on both SUV_max and HTV, which can be probably attributed to the presence of undetectable hypoxia with the current method. Besides, 18F-fluorodeoxyglucose (¹⁸F-FDG) and ⁶⁴Cu-ATSM provide similar results about delineation of biological tumor volume.

Several studies were conducted using ⁶⁰Cu in cervical cancer, and similar results in predicting the tumor response to therapy were obtained.¹⁸ In fact, the pattern and magnitude of tumor uptake of ⁶⁰Cu and ⁶⁴Cu-ATSM are similar even if image quality is better in ⁶⁴Cu than in ⁶⁰Cu.¹⁹ Therefore, ⁶⁴Cu-ATSM may be a predictive indicator of tumor response to therapy in patients with cervical cancer.

In 9 gliosarcoma rat models,²⁰ ⁶⁴Cu-ATSM uptake was measured in tumor tissue under different oxygen partial pressures (pO₂), and there was a good correlation between low pO₂ and high ⁶⁴Cu-ATSM accumulation. The uptake of ⁶⁴Cu-ATSM in tissues in vivo depends on the tissue pO₂, and significantly greater uptake and retention occur in hypoxic tumor tissue.

Since radiation resistance of hypoxic tumor is a well-known phenomenon, it is very important to assess the extent and location of hypoxia within a tumor. As a hypoxia imaging agent with high tumor-to-background ratios, ⁶⁴Cu-ATSM allows targeting of positive lesions with high sensitivity and specificity on PET. Hypoxia imaging-guided intensity-modulated radiation therapy can deliver higher dose of radiation to the hypoxic tumor and normal tissues.

However, some preclinical data suggested that ⁶⁴Cu-ATSM was not a hypoxia marker in all types of tumor. Vāvere et al ²⁴ found that the relationship between ⁶⁴Cu-ATSM and overexpression of fatty acid synthase (FAS) was associated with prostate cancer (PCa), and the physiological significance of the FAS pathway in PCa was the harnessing of its oxidizing power for improving redox balance (ie, lower NADH/NAD⁺ ratios), despite under oxygen-limiting (hypoxic) conditions causing low ⁶⁴Cu-ATSM uptake in hypoxic and normoxic regions. Therefore, the translation of ⁶⁴Cu-ATSM to imaging of PCa may be limited by the overexpression of FAS associated with prostatic malignancies.

⁶⁴Cu is not only useful for PET imaging but also has potential as an agent for internal radiotherapy, since its favorable β⁻ decay (38%) and Auger electrons emitted from this nuclide can damage tumor cells.^25,26 Yukie et al ²⁶ studied the therapeutic effect of ⁶⁴Cu-ATSM in HT-29 tumor-bearing mice after treating with bevacizumab, and the results showed that ⁶⁴Cu-ATSM effectively inhibited the growth of HT-29 tumors, exhibiting bevacizumab-induced vascular decrease and hypoxia. Therefore, it prolongs the survival of mice during bevacizumab treatment with negligible toxic side effects. Jason et al ²⁵ also found that ⁶⁴Cu-ATSM significantly increased the survival time of hamsters bearing human GW39 colon cancer tumors. Yoshii et al ²⁷ showed that the ⁶⁴Cu-ATSM uptake region of tumors was associated with upregulation of DNA repair and a high ratio of CD133⁺ cells. CD133⁺ cells have been reported to be highly resistant to conventional radiotherapy and chemotherapy in many types of cancer. ⁶⁴Cu-ATSM decreased the number of CD133⁺ cells not via specific interactions, but it was accumulated in CD133⁺ cell-rich regions within tumor, leading to higher doses of radiation in those areas.²⁸

⁶⁴CuCl₂

⁶⁴CuCl₂, as the substrate of CTR1, has been demonstrated as a promising PET tracer for imaging animal models with tumors, such as melanoma, glioblastoma multiform, and PCa.^29
–31 More importantly, some studies have shown that ⁶⁴CuCl₂-PET/CT is used in human study.^30,32 Peng et al ³¹ found that human PCa xenografts may be localized by PET using ⁶⁴CuCl₂ as a probe. Piccardo et al ³³ prospectively evaluated 50 patients with PCa and showed that ⁶⁴CuCl₂ PET/CT possessed a significantly higher detection rate than ¹⁸F-choline PET-CT. Jiang et al ³⁴ studied animal models of H₂O₂-induced muscle inflammation and lipopolysaccharide-induced lung inflammation and revealed that the inflammatory muscles and lungs had a significantly higher ⁶⁴Cu accumulation than their corresponding controls (P < .05). The potential diagnostic role of ⁶⁴CuCl₂ PET/CT imaging for brain malignancies has been recently evaluated in 19 patients with a documented history and radiologic evidence of cerebral tumors.³⁰ After initial cerebral magnetic resonance imaging (MRI), patients were administered with ⁶⁴CuCl₂ (13 MBq/kg), and brain PET/CT imaging was performed at 1, 3, and 24 hours after administration. Excellent agreement was found between PET/CT and MRI. Brain cancerous lesions can be clearly visualized within 1 hour after injection of ⁶⁴CuCl₂, with stable retention of radioactivity up to 24 hours. The radioactivity was cleared rapidly from the blood and mostly excreted through the liver. The major limitation of this study was that only a small number of patients were enrolled. However, these preliminary clinical data suggested that ⁶⁴CuCl₂ can be a potentially useful diagnostic agent for malignancies of the central nervous system (CNS).

⁶⁴Cu-Labeled Antibodies for Tumor Targeting

As a large class of biotechnologically created proteins, monoclonal antibodies (mAbs) have been increasingly used in immunotherapy, targeted drug delivery, and in vivo/in vitro diagnostics. Trastuzumab (breast cancer expressing human epidermal growth factor receptor [EGFR] 2 or human epidermal growth factor receptor [HER2]), cetuximab (targeting EGFR-expressing tumors), TRC105-Fab (targeting CD105), and etaracizumab (antibody against human α_νβ₃ integrin) are the main monoclonal antibodies for ⁶⁴Cu labeling for PET imaging.²

⁶⁴Cu-trastuzumab

HER2 status in breast cancer determines its therapeutic strategy.³⁵ Humanized anti-HER2 antibody trastuzumab is a well-established therapeutic strategy for HER2-positive breast cancer in neoadjuvant, adjuvant, and metastatic settings, and it increases overall survival for patients with HER2-positive breast cancer.³⁶ Several reports showed that ⁶⁴Cu-DOTA-trastuzumab PET imaging can be used to visualize primary and metastatic HER2-positive lesions^35

–38 and better identify patients who may benefit from these expensive and potentially toxic treatments through a noninvasive approach.

Sasada et al ³⁵ evaluated the concordance of HER2 expression in primary breast tumors between HER2-PET imaging and immunohistochemistry (IHC) in 38 patients with breast cancer. Significant difference in mean SUV_max value was found between HER2-positive and HER2-negative breast tumors, and SUV_max values were correlated with HER2-IHC scores (correlation coefficient = .619). When the cutoff value of SUV_max by HER2-PET imaging was set at 1.98, the sensitivity, specificity, and accuracy (the correctly identified fraction among the whole instances) were 83.3%, 88.2%, and 85.7%, respectively. Another study evaluated the feasibility and potential utility of ⁶⁴Cu-DOTA-trastuzumab PET/CT for lesion detection and uptake measurement in 6 patients with HER2-positive metastatic breast cancer.³⁷ After initial ¹⁸F-FDG PET/CT, patients were administered with 45 mg ⁶⁴Cu-DOTA-trastuzumab, and PET/CT imaging was performed 21 to 25 (day 1) and 47 to 49 (day 2) hours after injection of ⁶⁴Cu-DOTA-trastuzumab. The results showed that ⁶⁴Cu-DOTA-trastuzumab was rapidly accumulated in tumors after 1 hour of injection, and the detection sensitivity on day 1 and day 2 were 77% and 89%, respectively. Besides, no unanticipated toxicities or adverse side effects were observed in these 6 patients. The authors concluded that ⁶⁴Cu-DOTA-trastuzumab PET/CT was a practically and acceptably safe procedure in patients with metastatic breast cancer. A preliminary clinical study suggested that HER2-specific ⁶⁴Cu-DOTA-trastuzumab also accumulated in brain metastasis as evidenced by autoradiography, IHC, and liquid chromatography-tandem mass spectrometry.³⁸

⁶⁴Cu-cetuximab

EGFR is a member of the erbB family of tyrosine kinase receptors,³⁹ and the dysregulation of EGFR leads to several key features of cancer, such as autonomous cell growth, apoptosis and inhibition of angiogenesis, invasion, and metastases.⁴⁰ However, many studies have found that EGFR is overexpressed in many human tumors, including HNSCC, colon cancer, NSCLC, and cervical cancer.^41,42 Cetuximab with high affinity to EGFR, which was the first mAb against the EGFR or the treatment of patients with EGFR-expressing metastatic colorectal carcinoma approved by the US Food and Drug Administration.⁵ In recent decades, radio-labeled anti-EGFR antibodies, such as ⁶⁴Cu-cetuximab, were studied for diagnosis, monitoring, and efficacy evaluation of EGFR-expressing tumors.

Cai et al,⁴² for the first time, evaluated the quantitative PET imaging of EGFR expression in xenograft-bearing mice using ⁶⁴Cu-labeled cetuximab. In this study, 7 different types of cancer cell lines (U87MG human glioblastoma, PC-3 human prostate carcinoma, CT-26 murine colorectal carcinoma, HCT-8, HCT-116, and SW620 human colorectal carcinoma, and MDA-MB-435 human breast cancer) were selected, and a good correlation (R ² = .80) between the tracer uptake (measured by PET) and the EGFR expression (measured by Western blotting) was confirmed. As expected, ⁶⁴Cu-DOTA-cetuximab showed significantly increased accumulation of tumor activity over time in EGFR-positive tumors (U87MG and PC-3 tumors), but it had relatively low uptake in EGFR-negative tumors (<5% ID/g). The radioactivity was mainly cleared through the hepatic pathway, and virtually no renal uptake or renal clearance was observed. The results of this study further revealed the potential utility of cetuximab for tumor diagnosis using PET as well as for determining patient-specific therapies and therapeutic efficacy monitoring.

In another interesting study, Laura et al ⁴³ developed and characterized an EGFR-directed PET tracer, ⁶⁴Cu-cetuximab-F(ab′)2, to determine the systemic accessibility of EGFR. The authors selected male mice bearing human HNSCC xenografts UT-squamous cell carcinoma (SCC-8; n = 6) or UT-SCC-45 (n = 6). After 1 mouse for each tumor model was injected with excess unlabeled cetuximab (1 mg) for 3 days, ⁶⁴Cu-cetuximab-F(ab′)2 (21 ± 2.6 MBq,15 μg, 250 μL) PET/CT imaging was performed for UT-SCC-8and UT-SCC-45 mice. In vivo PET imaging and biodistribution studies demonstrated significant tumor uptake with good tumor-to-background signal at 24 hours after injection. The results indicated that ⁶⁴Cu-cetuximab-F(ab′)2 uptake was correlated with EGFR expression in both tumors, and UT-SCC-8 had a significantly higher expression of EGFR compared to UT-SCC-45. The preclinical data indicated the potential of ⁶⁴Cu-cetuximab-F(ab′)2 as a clinical EGFR-targeting tracer.

⁶⁴Cu-TRC105-Fab

Tumor cells rely on newly formed tumor vessels for adequate nutrition during tumor growth, without which they cannot grow beyond a critical size or metastasize to another organ.⁴⁴ In the past 2 decades, efforts were made to find specific markers for newly formed tumor angiogenesis, and many targets have been widely studied for noninvasive imaging of tumor angiogenesis.^45,46 CD105 is mainly overexpressed on proliferating endothelial cells, and it is a promising candidate for tumor vascular targeting. High CD105 intratumor microvessel density is correlated with lower patient survival rates in multiple solid cancers, such as breast cancer, gastrointestinal, cancer, and PCa.⁴⁷

As an accepted standard approach to identify actively proliferating tumor vessels, CD105 IHC has several potential advantages over the other targets, including overexpression in many solid malignancies, effective evaluation of the efficacy of antiangiogenic treatments, independence of its expression on neoplastic cells, lack of tumor histotype specificity, and immediate accessibility of malignant lesions through the blood stream.⁵ With good affinity and specificity for CD105 on the tumor vasculature, radiolabeled TRC105-Fab can be potentially used as a promising imaging and diagnostic vascular agent for PET imaging in human tumors.⁴⁵

Yin et al ⁴⁵ reported PET imaging of CD105 expression in 4T1 murine model of breast cancer using ^61/64Cu-NOTA-TRC105-Fab, exhibiting prominent and target-specific uptake in the 4T1 tumor. Besides, the use of a Fab fragment leads to much faster tumor uptake (which peaks at a few hours after tracer injection) compared to radio-labeled intact antibody, which may be translated into same-day immune-PET imaging for clinical investigation.

⁶⁴Cu-Integrin-Targeting Peptides

As a transmembrane glycoprotein receptor and an important cell adhesion molecule, alpha ν beta 3 (α_νβ₃) plays important roles in tumor growth, invasion, metastasis, and angiogenesis.⁴⁸ It is highly expressed on various types of tumor cells, including glioblastomas, breast cancer, PCa, malignant melanomas, and ovarian carcinomas.⁵ The cyclic pentapeptide containing a tripeptide sequence Arg-Gly-Asp (cRGD) has been identified with high specificity and affinity for the α_νβ₃.⁴⁸

Sprague et al ⁴⁹ evaluated ⁶⁴Cu-labeled c(RGDyK) peptides conjugated to a different chelator, CB-TE2A, and found that the corresponding ⁶⁴Cu complex was taken up specifically by osteoclasts, which were upregulated in osteolytic lesions and bone metastases. Ocak et al ⁵⁰ compared ⁶⁴Cu-labeled c(RGDyK) peptides with previously reported CB-TE2A conjugates of c(RGDyK) for imaging osteoclasts in the 4T1 mouse, a mammary tumor model of bone metastases. This study demonstrated that although all chelator-peptide conjugates showed similar binding affinity for integrin α_νβ₃, the in vivo tumor targeting of CB-TE1A1P was superior to CB-TE2A-c(RGDyK). There is also improved kidney function and liver clearance for ⁶⁴Cu-TE1A1P-DBCO-c(RGDyK). In addition, PET imaging with ⁶⁴Cu-labeled c(RGDyK) can be informative for diagnosis and/or monitoring treatment for other diseases with high levels of osteoclasts, such asosteoarthritis.^51,52

⁶⁴Cu-Somatostatin Analogues

Somatostatin (SST) receptors (SSTRs) are G-protein-coupled receptors expressed on cell membranes, and 5 subtypes of SSTRs (SSTRl to SSTR5) have been identified to date.⁵³ The SSTRs are highly expressed in neuroendocrine tumors (NETs), such as pheochromocytoma, pituitary adenoma, carcinoid tumor, and medullary thyroid carcinoma, but they are also positive on the cell surfaces of other non-neurocytic tumor cells, including gliomas, meningioma, small cell lung cancer, and neuroblastoma.⁵⁴

SST and its analogues bind to SSTRs with high affinity and high specificity, inactivate the signal transcription, and suppress the growth of corresponding tissue cells, thereby inhibiting the growth of tumor cells.⁵⁵ An 8-amino acid analog of SST, octreotide (OC), possesses a longer biologic half-life, and it is much more effective in inhibiting the secretion of growth hormone compared to SST.¹⁴ Several radiotracers containing an SST analog chelated to a radioisotope were developed for SSTR imaging.

Anderson et al ⁵⁶ demonstrated that ⁶⁴Cu-TETA-OC can be used to detect SSTR-positive tumors in humans. ⁶⁴Cu-TETA-OC PET shows higher rate of lesion detection, good sensitivity, favorable dosimetry, and pharmacokinetics for NET imaging compared to ¹¹¹In-DTPA-OC SPECT, partially due to the greater sensitivity of PET. Pfeifer et al ⁵⁷ prospectively studied 112 patients with pathologically confirmed NETs of gastroenteropancreatic or pulmonary origin and found that the diagnostic sensitivity, accuracy, and negative predictive value (NPV; the fraction of correctly identified as negatives among the whole instances that were identified as negatives) of ⁶⁴Cu-DOTA-TATE were higher than those of ¹¹¹In-DTPA-OC (97%, 97%, and 80% vs 87%, 88%, and 48%, respectively). Results showed that the diagnostic value of ⁶⁴Cu-DOTA-TATE in patients with NETs was significantly better than that of ¹¹¹In-DTPA-OC. Therefore, ⁶⁴Cu-TETA-OC can replace ¹¹¹In-DTPA-OC in diagnosis of NETs. A similar head-to-head comparison was conducted to assess the diagnostic value of ⁶⁴Cu-DOTA-TATE and ⁶⁸Ga-DOTA-TOC in 59 patients with NETs.⁵⁸ In the 68 inconsistent imaging areas, ⁶⁴Cu-DOTA-TATE showed 42 sites, of which 33 were found to be true positive (correctly identified instances) on follow-up. Moreover, 26 sites were detected by ⁶⁸Ga-DOTA-TOC, of which 7 were confirmed to be true-positive during follow-up. ⁶⁴Cu-DOTA-TATE finds an additional 83% of the true-positive sites, and the results showed that ⁶⁴Cu-DOTA-TATE had advantages over ⁶⁸Ga-DOTATOC in the detection of lesions in patients with NETs. In addition, ⁶⁴Cu-DOTA-TATE has a shelf life of more than 24 hours and a scanning window of at least 3 hours, making it advantageous and easy to use in a clinical setting.

Unfortunately, it was reported that Cu-TETA chelates were instable in vivo, since ⁶⁴Cu may dissociate from the TETA chelator and bind to proteins, primarily superoxide dismutase (SOD).⁵⁸ Using metabolism studies, Bass et al demonstrated that when ⁶⁴Cu-TETA-OC was injected into normal Sprague-Dawley rats, approximately 69% of the ⁶⁴Cu dissociates from ⁶⁴Cu-TETA-OC and binds to the protein SOD in the liver.⁵⁹ Clinical PET studies using ⁶⁴Cu-TETA-OC also resulted in retention of ⁶⁴Cu-TETA-OC in the blood and poor liver clearance in patients.⁵⁶ In another biodistribution study,⁵⁴ similar results were observed that ⁶⁴Cu-DOTA-TOC had a lower stability, showing slower blood clearance and high accumulation in the liver and intestine. Sun et al ⁶⁰ evaluated the radiochemistry and biodistribution of 4 ⁶⁴Cu-labeled cross-bridged cyclam ligands and found that ⁶⁴Cu-CB-TE2A (CB-TC2A-4, 11-bis (carboxymethyl)-1, 4, 8, 11- tetraazabicycl[6.6.2] hexadecane) had the most rapid clearance through blood, liver, and kidney compared to ⁶⁴Cu-TETA. Sarkar et al ⁶¹ investigated the biophysical and chemical properties of 5 closely related bifunctional chelators and showed that significant differences in tissue uptake and clearance patterns were dependent on the chelator utilized in the peptide conjugate. Conjugates containing propylene cross-bridged chelators show higher tumor uptake and ultrahigh in vivo stability, while a closely related ethylene cross-bridged analogue exhibits rapid body clearance.

Malmberg et al,⁶² for the first time, compared the large arterial uptake of ⁶⁸Ga-DOTA-TOC and ⁶⁴Cu-DOTA-TATE in 60 patients with NETs. The results showed that the uptake of ⁶⁴Cu-DOTA-TATE was significantly higher compared to ⁶⁸Ga-DOTA-TOC in the vascular regions. Besides, the uptake of ⁶⁴Cu-DOTA-TATE, but not ⁶⁸Ga-DOTA-TOC, was correlated with cardiovascular risk factors, suggesting a potential role for ⁶⁴Cu-DOTA-TATE in the assessment of atherosclerosis even in the subclinical stages.

⁶⁴Cu-AE105

Extensive amount of studies implicated that the serine protease urokinase-type plasminogen activator (uPA) and its receptor (uPAR) were strongly prognostic in cancer invasion and metastasis.^63,64 In line with this finding, several studies reported that uPAR was associated with poor prognosis and metastatic disease in various tumors, such as breast,⁶⁵ lung,⁶⁶ colorectal,⁶⁷ PCa,⁶⁸ and bladder⁶⁹ cancers. ⁶⁴Cu-DOTA-AE105 is a promising uPAR-PET ligand in several preclinical validation studies on PET imaging due to the high affinity of peptide antagonist AE105.⁷⁰

The first in-human use of ⁶⁴Cu-DOTA-AE105 dates back to 2013, when Persson et al ⁷¹ evaluated the safety, pharmacokinetics, and dosimetry of a single-dose injection of ⁶⁴Cu-DOTA-AE105 in cancer patients by serial PET-CT imaging. ⁶⁴Cu-DOTA-AE105 was well tolerated, and no adverse or clinically detectable side effects were found. The effective radiation dose was found to be 0.0276 mSv/MBq, and the liver was the organ with the highest absorption, followed by kidneys. In addition, high uptake in both primary tumor lesions and lymph node (LN) metastases were seen and paralleled by high uPAR expression in excised tumor tissue. The study concluded that uPAR-PET imaging seemed to be a highly promising technology with strong prognostic factor in patients with cancer. However, large controlled clinical trials have further indicated that these results are highly necessary.

⁶⁴Cu-Prostate-Specific Membrane Antigen Ligand 617

Prostate-specific membrane antigen (PSMA) is a unique cell membrane surface protein,⁷² which is overexpressed in PCa cells, particularly in advanced and metastatic disease, but its expression is limited in normal tissues. Low-molecular-weight radioligands have a relatively short cycle time and can be rapidly cleared from the target tissues.⁷³ Recently, 2-[3-(1-carboxy-5-{3-naphthalen-2-yl-2-[(4-{[2-(4,7,10-tris-carboxymethyl-1,4,7,10- tetraazacyclododec-1-yl) acetylamino]methyl} cyclohexanecarbonyl) amino] propionylamino} pentyl) ureido]-pentanedioic acid (PSMA-617) has been developed as a novel PSMA ligand. ⁶⁸Ga-PSMA PET/CT has a higher sensitivity than other radionuclides (¹⁸F) in the detection of PCa.⁷⁴ However, due to the short half-life of ⁶⁸Ga, its application is limited to clinical PET centers with radiochemistry facility and a ⁶⁸Ga generator available on site, and a limited accuracy is found in detecting small lesions and LNs with diameters <6 mm.⁷⁵ Recently, studies were conducted using the ⁶⁴Cu alternative ⁶⁸Ga label PSMA. Radionuclides with a longer half-life, such as ⁶⁴Cu (T_1/2 = 12.7 hours), allow sufficient time to clear nonspecific radioactivity in the background tissue, resulting in high tumor-to-organ ratios.⁷⁶ In addition, ⁶⁴Cu emits lower positron energy than ⁶⁸Ga, and therefore it has better image resolution.

The first in-human use of ⁶⁴Cu-labeled ligand PSMA-617 for PET imaging in PCa occurs at 2 different centers in Austria and Germany.⁷⁷ In this study, the advantages of a small PSMA-targeting agent and a long-lived positron emitter with good image quality were combined, and ⁶⁴Cu-PSMA-617 resulted in high image contrast. All cases with histologically proven local diseases (23 of 29 patients) were clearly identified by ⁶⁴Cu-PSMA-617 PET. Lesions suspicious for PCa were detected with excellent contrast as early as 1 hour post-injection, with high detection rates even at low prostate-specific antigen (PSA) levels. This study showed that ⁶⁴Cu-PSMA-617 PET/CT imaging had a high potential in the detection of PCa. Cantiello et al ⁷⁸ assessed the diagnostic accuracy of ⁶⁴Cu-PSMA-617 PET/CT in the primary LN staging of 23 patients with intermediate- to high-risk PCa. The final pathological results were used as reference standards. The results displayed that ⁶⁴Cu-PSMA PET/CT was always positive on PCa, and SUV_max at 4 hours were significantly increased compared to that at 5 minutes and 1 hour in PCa and in LN metastases. The sensitivity, specificity, PPV (positive predictive value, the fraction of correctly identified as positives among the whole instances that were identified as positives), and NPV for LN staging of ⁶⁴Cu-PSMA PET/CT at 4 hours were 87.5%, 100%, 100%, and 93.7%, respectively. The receiver operating characteristic (ROC) curve showed the accuracy of ⁶⁴Cu-PSMA PET/CT in LN staging was characterized by an area under the curve of 0.938. In addition, there was a positive correlation between the 4-hour SUV_max and Gleason score, index, and cumulative tumor volume. These preliminary studies indicated that ⁶⁴Cu-PSMA-617 PET/CT had high potential in the diagnosis and LN staging of patients with PCa, but further extensive clinical studies are still needed.

⁶⁴Cu-PSMA-617 is a novel radiotracer for tumor imaging not only in PCa but also expressed in many solid tumor angiogenic systems, such as gastric cancer and colon cancer.⁷⁹ The specificity of ⁶⁴Cu-PSMA-617 is confirmed by cell uptake experiments in PSMA(+) LNCaP cells as well as PSMA(−) PC-3 and gastric adenocarcinoma BGC-823 cells.⁸⁰

Other Applications

In the past period of time, nanodevices and nanoparticles were used in biomedical research to investigate improved diagnostic and therapeutic agents.¹⁴ When nanoparticles are linked to tumor targeting ligands, such as antibodies, proteins, peptides, or other biologically relevant small molecules, they can be used to target tumor antigens (biomarkers) as well as tumor vasculatures with high affinity and specificity.⁸¹

The studies assessed the use of ⁶⁴Cu-labeled DOTA-alendronate for PET imaging in normal or tumor-bearing aged, female, retired breeder Sprague-Dawley rats.⁸² PET images showed excellent contrast between mammary microcalcifications and surrounding soft tissues. The study indicated that different types of tumors had significantly different ⁶⁴Cu-DOTA-alendronate uptakes, the radioactivity uptake in malignant tumors was higher than that in benign and normal tissues, and these variations in uptake (and resultant PET image intensity) were inversely proportional to the radiopacity of these tumor types on traditional mammograms. At the same time, the dosimetric analysis demonstrated a ⁶⁴Cu effective dose within the acceptable range for clinical PET imaging agents and the potential for translation into patients.

Conclusions

⁶⁴Cu has an intermediate half-life of 12.7 hours and unique decay profile, making it a favorable option for radiolabeling peptides, small molecules, and large biomolecules, such as antibodies and nanoparticles for PET imaging and radionuclide therapy. The versatility of copper and its compounds makes it a powerful advantage in the development of new pharmaceuticals. This is conducive to the greater role of nuclear medicine imaging in the diagnosis and treatment of diseases and will have a profound impact on the formation of new medical models and human health. However, studies reported that ⁶⁴Cu-TATE/⁶⁴Cu-DOTA was instable in vivo, and ⁶⁴Cu may dissociate from the TETA or DOTA chelator. Therefore, significant research has been devoted to the development of ligands that can stably chelate ⁶⁴Cu.

Footnotes

Authors' Note

Yeye Zhou and Jihui Li contributed equally to this work.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was financially supported by National Natural Science Foundation of China (No. 81601522), Natural Science Foundation of Jiangsu Province (No. BK20160348), Medical Youth Talent Project of Jiangsu Province (No. QNRC2016749) and Science and Technology Project for the Youth of Suzhou (No. kjxw2015004).

ORCID iD

Yeye Zhou, MB

Abbreviations

References

Wadas

Wong

Weisman

Anderson

. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des. 2007;13(1):3–16.

Szymański

Frączek

Markowicz

Mikiciuk-Olasik

. Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals. 2012;25(6):1089–1112.

Zhu

. ⁶⁴Cu-Labeled multifunctional dendrimers for targeted tumor PET imaging. Nanoscale. 2018;10(13):6113–6124.

Follacchio

De Feo

De Vincentis

Monteleone

Liberatore

. Radiopharmaceuticals labelled with copper radionuclides: clinical results in human beings. Curr Radiopharm. 2018;11(1):22–33.

Niccoli Asabella

Cascini

Altini

Paparella

Notaristefano

Rubini

. The copper radioisotopes: a systematic review with special interest to ⁶⁴Cu. Biomed Res Int. 2014;2014:786463. doi:10.1155/2014/786463.

Chakravarty

Chakraborty

Dash

. ⁶⁴Cu2+ Ions as PET Probe: an emerging paradigm in molecular imaging of cancer. Mol Pharm. 2016;13(11):3601–3612. doi:10. 1021/acs. Molpharmaceut.6b00528.

Szelecsenyi

Blessing

Qaim

. Excitation function of proton induced nuclear reactions on enriched ⁶¹Ni and ⁶⁴Ni: possibility of production of no-carrier-added ⁶¹Cu and ⁶⁴Cu at a small cyclotron. Appl Radiat Isot. 1993;44(3):575–580.

Karimi

Sadeghi

Matajikojouri

. ⁶⁴Cu, a powerful positron emitter for immunoimaging and theranostic: production via ZnO and ZnO-NPs. Appl Radiat Isot. 2018;137:56–61. doi:10.1016/j.apradiso.2018.03.007.

McCarthy

Shefer

Klinkowstein

. Efficient production of high specific activity ⁶⁴Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24(1):35–43.

10.

Piel

Qaim

Stocklin

. Excitation functions of (p, xn)-reactions on nat Ni and highly enriched ⁶² Ni: possibility of production of medically important radioisotope 62 Cu on a small cyclotron. Radiochimica Acta. 1992;57:1–5.

11.

Shokeen

Anderson

. Molecular imaging of cancer with copper-64 radiophar rmaceuticals and positron emission tomography (PET). Acc Chem Res. 2009;42(7):832–841.

12.

Zinn

Chaudhuri

Cheng

Morris

Meyer

Jr . Production of no-carrier-added ⁶⁴Cu from zinc metal irradiated under boron shielding. Cancer. 1994;73(suppl 3):774–778.

13.

Colombié

Gouard

Frindel

. Focus on the controversial aspects of ⁶⁴Cu-ATSM in tumoral hypoxia mapping by PET imaging. Front Med (Lausanne). 2015;2:58.

14.

Anderson

Ferdani

. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm. 2009;24(4):379–393.

15.

Mccall

Humm

Bartlett

Reese

Carlin

. Copper-64-diacetyl-bis (N(4)- methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia. Int J Radiat Oncol Biol Phys. 2012;84(3):e393–e399. doi:10.1016/j.ijrobp.2012.0 5.005.

16.

Lopci

Grassi

Rubello

. Prognostic evaluation of disease outcome in solid tumors investigated with ⁶⁴Cu-ATSM PET/CT. Clin Nucl Med. 2016;41(2):e87–e92. doi:10.1097/RLU.0000000000001017.

17.

Grassi

Nanni

Cicoria

. Usefulness of ⁶⁴Cu-ATSM in head and neck cancer: a preliminary prospective study. Clin Nucl Med. 2014;39(1):e59–e63.

18.

Grigsby

Malyapa

Higashikubo

. Comparison of molecular markers of hypoxia and imaging with (60) Cu-ATSM in cancer of the uterine cervix. MolImaging Biol. 2007;9(5):278–283.

19.

Lewis

Laforest

Dehdashti

Grigsby

Welch

Siegel

. An imaging comparison of ⁶⁴Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med. 2008;49(7):1177–1182.

20.

Lewis

Sharp

Laforest

Fujibayashi

Welch

. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42(4):655–661.

21.

Fujibayashi

Taniuchi

Yonekura

Ohtani

Konishi

Yokoyama

. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38(7):1155–1160.

22.

Chen

. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol. 2011;38(1):70–86.

23.

Lopci

Grassi

Chiti

. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging. 2014;4(4):365–384.

24.

Vāvere

Lewis

. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nucl Med Biol. 2008;35(3):273–279. doi:10.1016/j.nucmedbio.2007.11. 012.

25.

Lewis

Laforest

Buettner

. Copper-64- Diacetyl-Bis(N4-Methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci U S A. 2001;98(3):1206–1211. doi:10.1073/pn as.98.3.1206.

26.

Yoshii

Yoshimoto

Matsumoto

. ⁶⁴Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts. Oncotarget. 2017;8(51):88815–88826.

27.

Yoshii

Furukawa

Matsumoto

. (64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133 (+) cells in an HT-29 tumor model: sensitization with a nucleic acid antimetabolite. Cancer Lett. 2016;376(1):74–82.

28.

Yoshii

Furukawa

Kiyono

. Internal radiotherapy with copper-64-diacetyl-bis(N4 - methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma. Nucl Med Biol. 2011;38(2):151–157.

29.

Qin

Liu

Chen

. Theranostics of malignant melanoma with ⁶⁴CuCl2. J Nucl Med. 2014;55(5):812–817.

30.

Panichelli

Villano

Cistaro

. Imaging of brain tumors with Copper-64 Chloride: early experience and results. Cancer Biother Radiopharm. 2016;31(5):159–167. doi:10.1089/cbr.2016. 2028.

31.

Peng

Janisse

Muzik

Shields

. PET of human prostate cancer xenografts in mice with increased uptake of ⁶⁴CuCl₂ . J Nucl Med. 2006;47(10):1649–1652.

32.

Avila-Rodriguez

Rios

Carrasco-Hernandez

. Biodistribution and radiation dosimetry of ⁶⁴Cu.copper dichloride: first-in- human study in healthy volunteers. EJNMMI Res. 2017;7(1):98.

33.

Piccardo

Paparo

Puntoni

. ⁶⁴CuCl PET/CT in prostate cancer relapse. J Nucl Med. 2018;59(3):444–451.

34.

Jiang

Song

Chen

Zhang

Wang

Cheng

. Pilot Study of ⁶⁴CuCl₂ for PET Imaging of Inflammation. Molecules. 2018;23(2):E502. doi:10.3390/molecules230 20502.

35.

Sasada

Kurihara

Kinoshita

. ⁶⁴Cu-DOTA-Trastuzumab PET imaging forHER2-specific primary lesions of breast cancer. Ann Oncol. 2017;28(8):2028–2029. doi:10.1093/annonc/mdx227.

36.

Mortimer

Bading

Park

. Tumor Uptake of ⁶⁴Cu-DOTA-trastuzumab in patients with metastatic breast cancer. J Nucl Med. 2018;59(1):38–43. doi:10. 2967 /jnumed.117.193888.

37.

Mortimer

Bading

Colcher

. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64) Cu-DOTA-trastuzumab PET. J Nucl Med. 2014;55(1):23–29. doi:10.2967/jnumed.113.122630.

38.

Kurihara

Hamada

Yoshida

. ⁶⁴Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res. 2015;5:8. doi:10.1186/s13550-0 15-0082-6.

39.

Arteaga

. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30(3 suppl 7):3–14.

40.

Ping Li

Meyer

Capretto

Sherman

Anderson

. Receptor-binding, biodistribution, and metabolism studies of ⁶⁴Cu- DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm. 2008;23(2):158–171. doi:10.1089/cbr.2007.0444.

41.

Eiblmaier

Meyer

Watson

Fracasso

Pike

Anderson

. Correlating EGFR expression with receptor-binding properties and internalization of ⁶⁴Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med. 2008;49(9):1472–1479.

42.

Cai

Chen

. Quantitative PET of EGFR expression in xenograft-bearing mice using ⁶⁴Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34(6):850–858. doi:10.1007/s00259-006 -0361-6.

43.

van Dijk

Yim

Franssen

. PET of EGFR with (64) Cu-cetuximab-F(ab’)2 in mice with head and neck squamous cell carcinoma xenografts. Contrast Media Mol Imaging. 2016;11(1):65–70. doi:10.1002/cmmi. 1659.

44.

Carmeliet

Jain

. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–257.

45.

Zhang

Hong

Orbay

. PET imaging of CD105 / endoglin expression with a ^61/64Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging. 2013;40(5):759–767.

46.

Zhang

Yang

Hong

Cai

. Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med. 2011;4(1):32–42.

47.

Dallas

Samuel

Xia

. Endoglin (CD105): a marker of tumor vasculature and potentialtarget for therapy. Clin Cancer Res. 2008;14(7):1931–1937.

48.

Jin

Furukawa

Degardin

. ανβ3 integrin-targeted radionuclide therapy with ⁶⁴Cu-cyclam-RAFT-c(-RGDfK-)4. Mol Cancer Ther. 2016;15(9):2076–2085.

49.

Sprague

Kitaura

Zou

. Noninvasive imaging of osteoclasts in parathyroid hormone–induced osteolysis using a ⁶⁴Cu-Labeled RGD Peptide. J Nucl Med. 2007;48(2):311–318.

50.

Ocak

Beaino

White

Zeng

Cai

Anderson

. Cu-labeled phosphonate cross-bridged chelator conjugates of c(RGDyK) for PET/CT imaging of osteolytic bone metastases. Cancer Biother Radiopharm. 2018;33(2):74–83.

51.

Sambrook

Cooper

. Osteoporosis. Lancet. 2006;367(9527):2010–2018.

52.

Nakamura

Duong

Rodan

. Involvement of alpha (v) beta3 integrins in osteoclast function. J Bone Miner Metab. 2007;25(6):337–344.

53.

Patel

. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198.

54.

Hanaoka

Tominaga

Yamada

. Evaluation of (64) Cu-labeled DOTA-D-Phe(1)–Tyr(3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors. Ann Nucl Med. 2009;23(6):559–567. doi:10.1007/s12149-009-0274-0.

55.

Anderson

Jones

Bass

. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med. 1998;39(11):1944–1951.

56.

Anderson

Dehdashti

Cutler

. ⁶⁴Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42(2):213–221.

57.

Pfeifer

Knigge

Binderup

. ⁶⁴Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA- Octreotide in 112 Patients. J Nucl Med. 2015;56(6):847–854.

58.

Johnbeck

Knigge

Loft

. Head-to-head comparison of ⁶⁴Cu-DOTATATE and ⁶⁸Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58(3):451–457. doi:10.2967/jnumed.116.180430.

59.

Bass

Wang

Welch

Anderson

. In vivo transchelation of copper-64 from TETA-octreotide to superoxidedismutase in rat liver. Bioconjug Chem. 2000;11(4):527–532.

60.

Sun

Wuest

Weisman

. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem. 2002;45(2):469–477.

61.

Sarkar

Bhatt

. High in Vivo Stability of ⁶⁴Cu-labeled cross-bridged chelators is a crucial factor in improved tumor imaging of RGD peptide conjugates. J Med Chem. 2018;61(1):385–395. doi:10.1021/acs.jmedch em.7b01671.

62.

Malmberg

Ripa

Johnbeck

. ⁶⁴Cu-DOTATATE for noninvasive assessment of atherosclerosis in large arteries and its correlation with risk factors: head-to-head comparison with ⁶⁸Ga-DOTATOC in 60 Patients. J Nucl Med. 2015;56(12):1895–1900. doi:10. 2967 /jnumed.115.161216.

63.

Persson

Kjaer

. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications. Clin Physiol FunctImaging. 2013;33(5):329–337.

64.

Dass

Ahmad

Azmi

Sarkar

. Evolving role of uPA / uPAR system in human cancers. Cancer Treat Rev. 2008;34(2):122–136.

65.

Riisbro

Christensen

Piironen

. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res. 2002;8(5):1132–1141.

66.

Pappot

Høyer-Hansen

Rønne

. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer. 1997;33(6):867–872.

67.

Pyke

Ralfkiaer

Rønne

Høyer-Hansen

Kirkeby

Danø

. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology. 1994;24(2):131–138.

68.

Akudugu

Serafin

Böhm

. Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. J Cancer Res Clin Oncol. 2015;141(4):627–631.

69.

Dohn

Illemann

Høyer-Hansen

. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder. Urol Oncol. 2015;33(4):165.e15–e24.

70.

Persson

El Ali

Binderup

. Dosimetry of ⁶⁴Cu-DOTA-AE105, a PET tracer for uPAR imaging. Nucl Med Biol. 2014;41(3):290–295.

71.

Persson

Skovgaard

Brandt-Larsen

. First-in-human uPAR PET: imaging of cancer aggressiveness. Theranostics. 2015;5(12):1303–1316.

72.

Ghosh

Heston

. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–539. doi:10.1002/jcb.10661.

73.

Cui

Hanyu

Hatori

. Synthesis and evaluation of (64) Cu. PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer. Am J Nucl Med Mol Imaging. 2017;7(2):40–52.

74.

Afshar-Oromieh

Zechmann

Malcher

. Comparison of PET imaging with a ⁶⁸Ga-labelled PSMA ligand and 18 F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med MolImaging. 2014;41(1):11–20.

75.

Budäus

Leyh-Bannurah

Salomon

. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393–396. doi:10.1016/j.eururo.2015.06.010.

76.

Banerjee

Pullambhatla

Foss

. 64 Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014;57(6):2657–2669.

77.

Grubmüller

Baum

Capasso

. (64)Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: first in-human studies. Cancer Biother Radiopharm. 2016;31(8):cbr.2015.1964.

78.

Cantiello

Gangemi

Cascini

. Diagnostic accuracy of (64)Copper prostate-specific membrane antigen positron emission tomography/computed tomography for primary lymph node staging of intermediate-to high-risk prostate cancer: our preliminary experience. Urology. 2017;106:139–145. doi:10.1016/j.urology.2017.04.019.

79.

Haffner

Kronberger

Ross

. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol. 2009;40(12):1754–1761.doi:10.1016/j.humpath.2009.06.003.

80.

Han

Liu

. ⁶⁴Cu-PSMA-617: a novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model. Oncotarget. 2017;8(43):74159–74169.

81.

Jain

. Recent advances in nanooncology. Technol Cancer Res Treat. 2008;7(1):1–13.

82.

Ahrens

Ciminera

. Diagnostic PET imaging of mammary microcalcifications using (64) Cu-DOTA-alendronate in a rat model of breast cancer. J Nucl Med. 2017;58(9):1373–1379.

64 Cu-based Radiopharmaceuticals in Molecular Imaging

Abstract

Keywords

Introduction

Production of Cu Radioisotope

64Cu-diacetyl-bis (N4-methylthiosemicarbazone)

64CuCl2

64Cu-Labeled Antibodies for Tumor Targeting

64Cu-trastuzumab

64Cu-cetuximab

64Cu-TRC105-Fab

64Cu-Integrin-Targeting Peptides

64Cu-Somatostatin Analogues

64Cu-AE105

64Cu-Prostate-Specific Membrane Antigen Ligand 617

Other Applications

Conclusions

Footnotes

Authors' Note

Declaration of Conflicting Interests

Funding

ORCID iD

Abbreviations

References

⁶⁴Cu-diacetyl-bis (N4-methylthiosemicarbazone)

⁶⁴CuCl₂

⁶⁴Cu-Labeled Antibodies for Tumor Targeting

⁶⁴Cu-trastuzumab

⁶⁴Cu-cetuximab

⁶⁴Cu-TRC105-Fab

⁶⁴Cu-Integrin-Targeting Peptides

⁶⁴Cu-Somatostatin Analogues

⁶⁴Cu-AE105

⁶⁴Cu-Prostate-Specific Membrane Antigen Ligand 617